Literature DB >> 16461304

Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival.

Isabelle Vande Broek1, Isabelle Van de Broek, Xavier Leleu, Rik Schots, Thiery Facon, Karin Vanderkerken, Ben Van Camp, Ivan Van Riet.   

Abstract

BACKGROUND AND OBJECTIVES: The capacity of multiple myeloma (MM) cells to home to and reside in the bone marrow implies that they must be equipped with appropriate adhesion molecules and chemokine receptors to allow transendothelial migration. We and others have previously shown that human MM cells express at least three different chemokine receptors that are functionally involved in MM cell migration, i.e. CCR1, CCR2 and CXCR4. In this study, we analyzed the surface expression of these chemokine receptors on primary MM cells from bone marrow samples. DESIGN AND METHODS: Chemokine receptor expression was analyzed on bone marrow samples from a large population of patients (n=80) by flow cytometric analysis. The chemokine receptor expression profile was compared with clinical characteristics. Statistical significance was evaluated by Fisher's exact test. Survival curves were constructed using the Kaplan-Meier method. Cox regression analysis was used to determine the effect of chemokine receptor expression on survival.
RESULTS: A heterogeneous expression pattern was observed for the three receptors tested. The chemokine receptor status (CRS) (i.e. no expression versus expression of at least one chemokine receptor), as well as expression of individual chemokine receptors was analyzed in relation to clinical and laboratory features and evaluated for prognostic significance. Chemokine receptor expression was significantly inversely correlated with disease activity: patients with active disease showed a significantly lower expression of CCR1, CCR2, as well as CXCR4 as compared to patients with non-active disease. Furthermore, the chemokine receptor expression profile correlated with serum beta2-microglobulin, C-reactive protein and hemoglobin. CRS, and the individual expressions of CCR1, CCR2 and CXCR4 in diagnostic bone marrow samples (n=70) correlated with survival. Multivariate analysis, using the Cox proportional hazard regression model, identified CRS, along with serum beta-microglobulin, as an independent prognostic factor. INTERPRETATION AND
CONCLUSIONS: This study indicates that the chemokine receptor expression profile of MM cells correlates with disease status and survival of MM patients. This observation might reflect impaired chemoattraction and retention of MM cells within the bone marrow microenvironment, resulting in disease progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16461304

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  26 in total

1.  Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

Authors:  Yazan Alsayed; Hai Ngo; Judith Runnels; Xavier Leleu; Ujjal K Singha; Costas M Pitsillides; Joel A Spencer; Teresa Kimlinger; Joanna M Ghobrial; Xiaoying Jia; Ganwei Lu; Michael Timm; Ashok Kumar; Daniel Côté; Israel Veilleux; Karen E Hedin; G David Roodman; Thomas E Witzig; Andrew L Kung; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

2.  The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis.

Authors:  Xuebin Yang; William Walton; Donald N Cook; Xiaoyang Hua; Stephen Tilley; Christopher A Haskell; Richard Horuk; A William Blackstock; Suzanne L Kirby
Journal:  Am J Respir Cell Mol Biol       Date:  2010-09-24       Impact factor: 6.914

3.  Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).

Authors:  Silke Cameron; Marieke Gieselmann; Martina Blaschke; Giuliano Ramadori; Laszlo Füzesi
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.

Authors:  Arghya Ray; Yan Song; Ting Du; Dharminder Chauhan; Kenneth C Anderson
Journal:  Oncogene       Date:  2020-02-05       Impact factor: 9.867

5.  CXCR6 deficiency attenuates pressure overload-induced monocytes migration and cardiac fibrosis through downregulating TNF-α-dependent MMP9 pathway.

Authors:  Jia-Hong Wang; Feng Su; Shijun Wang; Xian-Cheng Lu; Shao-Heng Zhang; De Chen; Nan-Nan Chen; Jing-Quan Zhong
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

6.  The influence of different microenvironments on melanoma invasiveness and microcirculation patterns: an animal experiment study in the mouse model.

Authors:  Baocun Sun; Shiwu Zhang; Danfang Zhang; Yanjun Gu; Wenchao Zhang; Xiulan Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-16       Impact factor: 4.553

7.  Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.

Authors:  Holly A F Stessman; Linda B Baughn; Aaron Sarver; Tian Xia; Raamesh Deshpande; Aatif Mansoor; Susan A Walsh; John J Sunderland; Nathan G Dolloff; Michael A Linden; Fenghuang Zhan; Siegfried Janz; Chad L Myers; Brian G Van Ness
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

Review 8.  Extravasation and homing mechanisms in multiple myeloma.

Authors:  Isabelle Vande Broek; Karin Vanderkerken; Benjamin Van Camp; Ivan Van Riet
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

9.  Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.

Authors:  Masahiro Abe; Kenji Hiura; Shuji Ozaki; Shinsuke Kido; Toshio Matsumoto
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

Review 10.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.